Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1998;7(2):111–114. doi: 10.1080/09629359891261

Levels of soluble Fas/APO-1 in patients with Behçet's disease.

K Hamzaoui 1, A Hamzaoui 1, L Zakraoui 1, A Chabbou 1
PMCID: PMC1781828  PMID: 9836498

Abstract

The aim of this study was to quantify soluble Fas/APO-1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Increased serum sFas/APO-1 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas/APO-1 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas/APO-1 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas/APO-1 are associated with the clinical stage and clinical manifestations in BD.

Full Text

The Full Text of this article is available as a PDF (131.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderson M. R., Tough T. W., Davis-Smith T., Braddy S., Falk B., Schooley K. A., Goodwin R. G., Smith C. A., Ramsdell F., Lynch D. H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995 Jan 1;181(1):71–77. doi: 10.1084/jem.181.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  3. Aydìntug A. O., Tokgöz G., D'Cruz D. P., Gürler A., Cervera R., Düzgün N., Atmaca L. S., Khamashta M. A., Hughes G. R. Antibodies to endothelial cells in patients with Behçet's disease. Clin Immunol Immunopathol. 1993 May;67(2):157–162. doi: 10.1006/clin.1993.1059. [DOI] [PubMed] [Google Scholar]
  4. Cheng J., Zhou T., Liu C., Shapiro J. P., Brauer M. J., Kiefer M. C., Barr P. J., Mountz J. D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994 Mar 25;263(5154):1759–1762. doi: 10.1126/science.7510905. [DOI] [PubMed] [Google Scholar]
  5. Cohen J. J., Duke R. C., Fadok V. A., Sellins K. S. Apoptosis and programmed cell death in immunity. Annu Rev Immunol. 1992;10:267–293. doi: 10.1146/annurev.iy.10.040192.001411. [DOI] [PubMed] [Google Scholar]
  6. Eglin R. P., Lehner T., Subak-Sharpe J. H. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulcers. Lancet. 1982 Dec 18;2(8312):1356–1361. doi: 10.1016/s0140-6736(82)91268-5. [DOI] [PubMed] [Google Scholar]
  7. Fortune F., Walker J., Lehner T. The expression of gamma delta T cell receptor and the prevalence of primed, activated and IgA-bound T cells in Behçet's syndrome. Clin Exp Immunol. 1990 Nov;82(2):326–332. doi: 10.1111/j.1365-2249.1990.tb05447.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hamzaoui A., Hamzaoui K., Chabbou A., Ayed K. Endothelin-1 expression in serum and bronchoalveolar lavage from patients with active Behçet's disease. Br J Rheumatol. 1996 Apr;35(4):357–358. doi: 10.1093/rheumatology/35.4.357. [DOI] [PubMed] [Google Scholar]
  9. Hamzaoui A., Hamzaoui K., Kooli C., Chabbou A., Hentati F., Ayed K. High levels of bcl-2 protein in the T lymphocytes of patients with Behçet's disease. Clin Exp Rheumatol. 1996 Jan-Feb;14(1):106–107. [PubMed] [Google Scholar]
  10. Hamzaoui K., Hamzaoui A., Hentati F., Kahan A., Ayed K., Chabbou A., Ben Hamida M., Hamza M. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behçet's disease. J Rheumatol. 1994 Dec;21(12):2301–2306. [PubMed] [Google Scholar]
  11. Hamzaoui K., Hentati F., Hamzaoui A., Kahan A., Ben Hamida M., Chabbou A., Ayed K. CD11/CD18 bearing lymphocytes in cerebrospinal fluid from patients with active Behçet's disease. Clin Exp Rheumatol. 1994 Sep-Oct;12(5):575–576. [PubMed] [Google Scholar]
  12. Hamzaoui K., Kahan A., Hamza M., Ayed K. Suppressive T cell function of Epstein-Barr virus induced B cell activation in active Behçet's disease. Clin Exp Rheumatol. 1991 Mar-Apr;9(2):131–135. [PubMed] [Google Scholar]
  13. Knipping E., Krammer P. H., Onel K. B., Lehman T. J., Mysler E., Elkon K. B. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum. 1995 Dec;38(12):1735–1737. doi: 10.1002/art.1780381205. [DOI] [PubMed] [Google Scholar]
  14. Mizushima Y., Matsuda T., Hoshi K., Ohno S. Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol. 1988 Jun;15(6):1029–1030. [PubMed] [Google Scholar]
  15. Mountz J. D., Zhou T., Su X., Wu J., Cheng J. The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S2–14. doi: 10.1006/clin.1996.0136. [DOI] [PubMed] [Google Scholar]
  16. Mysler E., Bini P., Drappa J., Ramos P., Friedman S. M., Krammer P. H., Elkon K. B. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest. 1994 Mar;93(3):1029–1034. doi: 10.1172/JCI117051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ogawa N., Dang H., Talal N. Apoptosis and autoimmunity. J Autoimmun. 1995 Feb;8(1):1–19. doi: 10.1006/jaut.1995.0001. [DOI] [PubMed] [Google Scholar]
  18. Raedler A., Bredow G., Kirch W., Thiele H. G., Greten H. In vivo activated peripheral T cells in autoimmune disease. J Clin Lab Immunol. 1986 Apr;19(4):181–186. [PubMed] [Google Scholar]
  19. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  20. Trauth B. C., Klas C., Peters A. M., Matzku S., Möller P., Falk W., Debatin K. M., Krammer P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989 Jul 21;245(4915):301–305. doi: 10.1126/science.2787530. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES